TABLE 1.
Clinical details of patients
| Age (y) | Sex | Method of diagnosis and/type of tissue sample | ALK detection | Stage | Smoking history pack‐year | Prior treatment | ALK inhibitor | Efficacy | PFS (m) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 54 | F | Bronchial biopsy | IHC | IV | Non‐smoker | PDC | Crizotinib | SD | 6.0 |
| Case 2 | 76 | M | Lung biopsy | IHC | IV | Smoker | PDC | None | ||
| Case 3 | 53 | M | Lung biopsy operation | IHC, | IIIa | Smoker | Adjunctive PDC | None | ||
| Case 4 | 35 | F | Lung biopsy cervical lymph node | IHC, | IV | Non‐smoker | PDC | Crizotinib | PD | 1.0(Dead) |
| Case 5 | 64 | M | Bronchial biopsy/surgery | IHC, | II | Smoker | None | None | ||
| Case 6 | 64 | M | Bronchial biopsy/surgery | IHC | IIIa | Smoker | Adjunctive PDC | None | ||
| Case 7 | 63 | M | Bronchial biopsy/surgery | IHC | I | Non‐smoker | PDC | None | ||
| Case 8 | 64 | M | Bronchial biopsy /surgery | IHC | IIIa | Smoker | Adjunctive PDC | None |
Abbreviations: F, female; FISH, fluorescence in situ hybridization; M, male; m, months; PD, progressive; PDC, platinum‐doublet chemotherapy; PFS, progression‐free survival; PR, partial response; RT‐PCR, reverse transcription polymerase chain reaction; SD, stable disease; y, year.